Evolus (EOLS) Stock Price, News & Analysis

Company Overview

Evolus, Inc. (NASDAQ: EOLS) is a specialty pharmaceutical company focused on aesthetic medicine, with its flagship product Jeuveau, a prescription neurotoxin designed for cosmetic use. Headquartered in Newport Beach, California, Evolus has positioned itself as a challenger brand in the Botox® market by targeting the growing demand for injectable treatments that reduce the appearance of glabellar lines. The company emphasizes strategic marketing, training and support for aesthetic providers to drive adoption and educate practitioners on best practices.

Jeuveau, also marketed as Nuceiva® in select European territories, received approval from the U.S. Food and Drug Administration in 2019 and later secured CE Mark authorization for sale in the European Economic Area. Evolus employs a direct-to-consumer advertising model, leveraging digital platforms and social media to raise awareness among prospective patients, while providing medical education and training through its Evolus Academy. This integrated approach aims to enhance treatment outcomes and foster long-term relationships with dermatologists, plastic surgeons and other aesthetic professionals.

Since its founding in 2017, Evolus has expanded its geographic footprint beyond the United States, entering key markets in Western Europe and planning further international growth. The company’s operational strategy includes building a scalable commercial infrastructure, forming partnerships with regional distributors and tailoring marketing initiatives to local regulatory environments. This global expansion underscores Evolus’s ambition to become a leading player in the aesthetic pharmaceutical sector.

Leadership at Evolus is spearheaded by CEO Michael Macaluso, who brings extensive experience in consumer and pharmaceutical industries. The management team combines expertise in product development, regulatory affairs and commercial execution, supporting ongoing efforts to diversify the company’s pipeline. Looking ahead, Evolus is pursuing additional clinical programs and has signaled interest in complementary aesthetic products such as dermal fillers and skincare technologies, reinforcing its commitment to innovation in aesthetic medicine.

Key Stats

• Today's Range: $9.45 to $9.75
• 50-Day Range: $9.10 to $12.08
• 52-Week Range: $8.67 to $17.82
• Volume: 852,343 shs
• Average Volume: 762,600 shs
• Market Capitalization: $611.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.75
• Consensus Rating: Buy

Evolus Stock Analysis - MarketRank™

Evolus scored higher than 78% of companies evaluated by MarketBeat, and ranked 242nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Evolus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Evolus has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Evolus are expected to grow in the coming year, from ($0.61) to ($0.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Evolus is -10.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evolus is -10.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Evolus has a P/B Ratio of 105.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.78% of the float of Evolus has been sold short.

Short Interest Ratio / Days to Cover

Evolus has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Evolus has recently increased by 13.10%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evolus does not currently pay a dividend.

Dividend Growth

Evolus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.5 / 5
• Environmental Score: -1.27

Percentage of Shares Shorted

19.78% of the float of Evolus has been sold short.

Short Interest Ratio / Days to Cover

Evolus has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Evolus has recently increased by 13.10%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.52

News Sentiment

Evolus has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Evolus this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for EOLS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

1 people have added Evolus to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Evolus insiders have sold 713.28% more of their company's stock than they have bought. Specifically, they have bought $189,000.00 in company stock and sold $1,537,090.00 in company stock.

Percentage Held by Insiders

Only 5.90% of the stock of Evolus is held by insiders.

Percentage Held by Institutions

90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EOLS Stock Analysis - Frequently Asked Questions

How have EOLS shares performed this year?

Evolus' stock was trading at $11.04 on January 1st, 2025. Since then, EOLS stock has decreased by 14.1% and is now trading at $9.48.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) announced its earnings results on Tuesday, March, 23rd. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.18. The firm had revenue of $20.58 million for the quarter, compared to analysts' expectations of $20.60 million. Evolus had a negative net margin of 20.40% and a negative trailing twelve-month return on equity of 759.04%.
Read the conference call transcript.

When did Evolus IPO?

Evolus (EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Who are Evolus' major shareholders?

Top institutional shareholders of Evolus include Assenagon Asset Management S.A. (0.95%). Insiders that own company stock include Alphaeon 1 Llc, Medytox Inc, David Moatazedi, Rui Avelar, Vikram Malik, Sandra Beaver, Tomoko Yamagishi-Dressler, Albert G White III, David N Gill, David N Gill and Robert Hayman.
View institutional ownership trends.

How do I buy shares of Evolus?

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Evolus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evolus investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 3/23/2021
• Today: 7/11/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EOLS
• CIK: 1570562
• Web: www.evolus.com
• Phone: (949) 284-4555
• Fax: N/A
• Employees: 170
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Evolus: $23.75
• High Price Target: $27.00
• Low Price Target: $21.00
• Potential Upside/Downside: +147.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$50.42 million
• Net Margins: -20.40%
• Pretax Margin: -20.15%
• Return on Equity: -759.04%
• Return on Assets: -20.14%

Debt

• Debt-to-Equity Ratio: 22.00
• Current Ratio: 2.34
• Quick Ratio: 2.16

Sales & Book Value

• Annual Sales: $266.27 million
• Price / Sales: 2.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.09 per share
• Price / Book: 106.53

Miscellaneous

• Outstanding Shares: 64,480,000
• Free Float: 60,672,000
• Market Cap: $618.23 million
• Optionable: Optionable
• Beta: 0.97